PMID- 31125272
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 60
IP  - 13
DP  - 2019 Dec
TI  - Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after 
      discontinuation of frontline ponatinib therapy.
PG  - 3172-3180
LID - 10.1080/10428194.2019.1617862 [doi]
AB  - Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials 
      in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were 
      terminated. We conducted a retrospective CML-CP outcome study of patients who 
      discontinued frontline-ponatinib. Among 51 patients who received frontline 
      ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib 
      discontinuation, all patients remained in CP with deepest response being CCyR, 
      n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at 
      ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of 
      seven patients, in CCyR at discontinuation, five improved response to MMR or 
      deeper, one was inevaluable, and another lost response due to treatment 
      noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% 
      and 96%, respectively, indicating favorable long-term outcomes. The 
      cardiac/vascular system AEs with subsequent TKI occurred in patients with prior 
      similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.
FAU - Boddu, Prajwal
AU  - Boddu P
AUID- ORCID: 0000-0001-9408-5882
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Jain, Preetesh
AU  - Jain P
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Borthakur, Gautam
AU  - Borthakur G
AUID- ORCID: 0000-0001-7679-6453
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Verstovsek, Srdan
AU  - Verstovsek S
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Garcia-Manero, Guillermo
AU  - Garcia-Manero G
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Daver, Naval
AU  - Daver N
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Kadia, Tapan
AU  - Kadia T
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Ravandi, Farhad
AU  - Ravandi F
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Jabbour, Elias
AU  - Jabbour E
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Cortes, Jorge
AU  - Cortes J
AUID- ORCID: 0000-0002-8636-1071
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
LA  - eng
GR  - P01 CA049639/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190524
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Imidazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridazines)
RN  - 4340891KFS (ponatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Imidazoles/*administration & dosage/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Chronic-Phase/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyridazines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Thrombosis/chemically induced/*epidemiology/prevention & control
MH  - *Withholding Treatment
MH  - Young Adult
OTO - NOTNLM
OT  - Ponatinib
OT  - chronic myeloid leukemia
OT  - chronic phase
OT  - frontline
OT  - outcomes
EDAT- 2019/05/28 06:00
MHDA- 2020/09/10 06:00
CRDT- 2019/05/25 06:00
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2019/05/25 06:00 [entrez]
AID - 10.1080/10428194.2019.1617862 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2019 Dec;60(13):3172-3180. doi: 10.1080/10428194.2019.1617862. 
      Epub 2019 May 24.